<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954106</url>
  </required_header>
  <id_info>
    <org_study_id>JZP395-201</org_study_id>
    <nct_id>NCT03954106</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity</brief_title>
  <official_title>Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Receiving Axicabtagene Ciloleucel (Yescarta®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-arm study evaluating the safety and efficacy of
      defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or
      refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CAR-T-associated neurotoxicity</measure>
    <time_frame>By CAR-T Day +30</time_frame>
    <description>Incidence of CAR-T-associated neurotoxicity (any grade, defined by CTCAE v5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of CAR-T-associated neurotoxicity of Grade 3 or greater</measure>
    <time_frame>By CAR-T Day +30</time_frame>
    <description>CAR-T-associated neurotoxicity of Grade 3 or greater defined by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CAR-T-associated neurotoxicity of any grade and Grade 3 or greater</measure>
    <time_frame>By CAR-T Day +30</time_frame>
    <description>CAR-T-associated neurotoxicity (any grade and Grade 3 or greater) according to the ASBMT consensus grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CRS</measure>
    <time_frame>By CAR-T Day +30</time_frame>
    <description>Incidence of CRS (any grade, according to the ASBMT consensus grading system)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of high dose steroid by CAR-T Day +30</measure>
    <time_frame>By CAR-T Day +30</time_frame>
    <description>The use of high dose steroids is defined as a dose of dexamethasone of at least 7.5 mg/day or equivalent</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>DLBCL</condition>
  <condition>Neurotoxicity Syndromes</condition>
  <arm_group>
    <arm_group_label>Defibrotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.
After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>Once daily on CAR-T Day -5, -4, -3 before lymphodepletion and also every 6 hours daily on CAR-T Day 0-7.</description>
    <arm_group_label>Defibrotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be ≥ 18 years of age at signing of informed consent.

          2. Subject must be diagnosed with relapsed or refractory DLBCL (including DLBCL not
             otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell
             lymphoma, and DLBCL arising from follicular lymphoma) and scheduled to receive
             treatment with Yescarta.

          3. Female subjects of childbearing potential who are sexually active and male subjects
             who are sexually active and have female partners of childbearing potential must agree
             to use a highly effective method of contraception with their partners during exposure
             to defibrotide and for 30 days after the last dose of defibrotide.

          4. Subject must be able to understand and sign written informed consent.

        Exclusion Criteria:

          1. Subject is currently receiving dialysis or expected to receive dialysis.

          2. Subject has used any investigational anticancer agent within 3 weeks prior to the
             first dose of defibrotide, or is using or plans to use any investigational agent
             during the study.

          3. Subject has previously been treated with CAR-T therapy.

          4. Hemodynamic instability requiring vasopressors or uncontrolled hypertension with
             persistent systolic blood pressure &gt; 180.

          5. Subject has clinically significant active bleeding, history of intracranial bleeding,
             or is at risk for intracranial bleeding as determined by the Investigator.

          6. Subject plans to use any medication that increases the risk of bleeding.

          7. Subject is pregnant or lactating and does not agree to stop breastfeeding.

          8. Subject has a known history of hypersensitivity to defibrotide or any of the
             excipients.

          9. Subject has primary CNS lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>2159707145</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

